Analytical Data
-
Gene name
DFNA5
- Application
-
Alternative Names
ICERE-1; Non-Syndromic Hearing Impairment Protein 5; Inversely correlated with estrogen receptor expression 1
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Z2D3
-
Expression Region
Met1~Asp512
-
Molecular Weight
60kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DFNA5 is a gene that has garnered significant attention due to its association with hereditary hearing loss, particularly in the context of non-syndromic auditory dysfunction. Mutations in DFNA5 can lead to progressive sensorineural hearing loss, making it crucial for understanding the molecular mechanisms underlying auditory pathways. Research has demonstrated that DFNA5 encodes a protein involved in cellular stress responses, particularly in the inner ear's hair cells, which are essential for sound transduction. The DFNA5 protein may interact with various cellular pathways, including those regulating apoptosis and inflammation, hinting at its potential role in maintaining cellular homeostasis within auditory structures. Moreover, the study of its recombinant protein has opened avenues for exploring therapeutic interventions, as understanding its structure and function could lead to targeted strategies to mitigate hearing loss associated with DFNA5 mutations. Recent advancements in gene therapy and molecular biology techniques further enhance the feasibility of developing effective treatments, making DFNA5 a focal point in auditory research and a promising target for future studies aimed at preventing or reversing hearing impairments linked to genetic factors. Overall, investigations into DFNA5 and its recombinant protein have the potential to considerably advance our understanding of hereditary hearing loss, offering insights that could translate into clinical applications for affected individuals.
